Sacutan
Generic Name
Sacubitril/Valsartan
Manufacturer
Genesis Pharma Limited
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| sacutan 49 mg tablet | ৳ 85.00 | ৳ 850.00 |
Description
Overview of the medicine
Sacutan 49 mg tablet is an Angiotensin Receptor-Neprilysin Inhibitor (ARNI) used for the treatment of chronic heart failure with reduced ejection fraction in adult patients.
Uses & Indications
Dosage
Adults
Initial dose: 49 mg Sacubitril/51 mg Valsartan orally twice daily. The dose should be doubled at 2-4 week intervals to a target dose of 97 mg Sacubitril/103 mg Valsartan twice daily, as tolerated.
Elderly
No specific dose adjustment is required based on age alone, but clinical judgment should be exercised. Start with the lowest dose (24 mg/26 mg) if patients are not currently taking ACE inhibitors or ARBs, and titrate gradually.
Renal_impairment
For severe renal impairment (eGFR <30 mL/min/1.73 m²), consider an initial dose of 24 mg Sacubitril/26 mg Valsartan twice daily. No initial dose adjustment is required for mild to moderate renal impairment.
How to Take
Take Sacutan 49 mg tablet orally, with or without food. Swallow the tablet whole with water. Do not crush or chew.
Mechanism of Action
Sacubitril inhibits neprilysin, an enzyme that degrades natriuretic peptides, leading to increased levels of these peptides. Valsartan is an angiotensin II receptor blocker (ARB) which antagonizes the effects of angiotensin II. The combined action results in vasodilation, natriuresis, and reduction of cardiac remodeling.
Pharmacokinetics
Onset
Symptomatic improvement in heart failure can take several weeks of consistent therapy. Blood pressure reduction may be observed sooner.
Excretion
Approximately 52% of the dose is excreted in urine and 37% in feces as LBQ657 and valsartan and their metabolites.
Half life
The effective half-life of LBQ657 (active sacubitril metabolite) is approximately 10-14 hours. The half-life of valsartan is approximately 9-10 hours.
Absorption
Sacubitril is a prodrug rapidly converted to the active metabolite LBQ657 by esterases. Valsartan is absorbed directly. Peak plasma concentrations for LBQ657 and valsartan are reached in 2-3 hours and 1.5 hours, respectively.
Metabolism
Sacubitril is extensively metabolized to its active metabolite LBQ657. Valsartan is minimally metabolized.
Side Effects
Contraindications
- •Concomitant use with ACE inhibitors (must be a 36-hour washout period).
- •History of angioedema related to previous ACE inhibitor or ARB therapy.
- •Known hypersensitivity to sacubitril or valsartan or any other excipients.
- •Pregnancy.
Drug Interactions
Lithium
Increased serum lithium concentrations and lithium toxicity have been reported. Monitor serum lithium levels.
Aliskiren
Not recommended in patients with diabetes or renal impairment (eGFR <60 mL/min/1.73 m²).
ACE Inhibitors
Concomitant use is contraindicated due to increased risk of angioedema. A 36-hour washout period is required between stopping an ACE inhibitor and initiating Sacubitril/Valsartan.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
May reduce the antihypertensive effect and potentially worsen renal function, especially in elderly, volume-depleted, or renally impaired patients.
Potassium-Sparing Diuretics/Potassium Supplements
May lead to increased serum potassium levels and hyperkalemia.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited data are available for overdose. Hypotension and hyperkalemia would be the most likely effects. Treatment is symptomatic and supportive. Sacubitril/Valsartan is not expected to be dialyzable.
Pregnancy & Lactation
Pregnancy: Contraindicated due to risk of fetal injury and death. Lactation: Not recommended. It is unknown whether components are excreted in human milk, but due to potential serious adverse reactions in breastfed infants, a decision should be made whether to discontinue nursing or the drug.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
2-3 years from manufacturing date
Availability
Pharmacies, Hospitals
Approval Status
Approved by regulatory bodies (e.g., FDA, DGDA)
Patent Status
Patented
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
